ClinicalTrials.gg
Active, not recruitingNCT07245953Updated Oct 29, 2026

A Clinical Study of HT-101 and HT-102 in Patients With Chronic Hepatitis B Virus Infection

A Phase 2 interventional study of HT-101 and HT-102 in Chronic Hepatitis B, sponsored by Suzhou HepaThera Biotech Co., Ltd.. Active, not recruiting at 12 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Suzhou HepaThera Biotech Co., Ltd. · Phase 2, Interventional, and Treatment

Updated Oct 29, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 375 studies in Hepatitis B, Chronic with a site in China — 89 open to participants now, 110 under way, 7 of them phase 3. Hepatitis B, Chronic · China.

Planned enrollment
204th of 273
60 · median 120
Started
2025
with 22 others
Phase 2
72 of 375
15 open now
Primary completion
2027-02
later than 55 of 109 live
Registered
338th of 375
by date

Among the 375 studies in Hepatitis B, Chronic with a site in China, this one is the 204th largest by planned enrollment of the 273 interventional ones that give a count, is one of 23 that started in 2025, is one of 72 in phase 2, reaches primary completion later than 55 of the 109 other live ones, and was the 338th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

89 of the 375 studies in Hepatitis B, Chronic with a site in China are open now. Recruiting first, the newest first:

84 more — sign in →

All 89 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 375 studies in Hepatitis B, Chronic with a site in China, or all of them as a file.
02

Study summary

This study is A multicenter, randomized, double-blind, placebo-controlled phase 2 clinical study to evaluate the efficacy and safety of HT-101 injection combined with HT-102 injection in patients with chronic hepatitis B. It consists of two phases: the main trial and the extension period. The main trial phase aims to explore the efficacy of different courses of HT-101 injection combined with HT-102 injection in treating patients with chronic hepatitis B and evaluate the optimal treatment strategy. The extension period phase, based on the main trial, assesses the long-term safety and efficacy of HT-101 injection combined with HT-102 injection.

03

Conditions studied

  • Chronic Hepatitis B

Browse trials for

04

Who can participate

The criteria were revised on the registry on Oct 29, 2026. See what changed

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects were eligible for inclusion into the study if they met each of the following criteria:

    • Patient with CHB;
    • Male subjects weighed ≥ 45.0 kg, female subjects weighed ≥ 40.0 kg, with a (BMI) between 19.0 and 30.0 kg/m\^2 (inclusive);
    • Chronic infection for >/= 6 months;
    • The quantitation level of HBsAg was > 100 IU/mL and \<3000 IU/mL; The quantitation level of HBV DNA \<LLOQ;
    • On Nas therapy for >/= 6 months at the time of screening;
    • Subjects promised to use effective for at least 1 month before screening, and have no fertility, donate sperm or eggs and voluntarily take highly effective physical contraception (including partners) during the trial and within 3 months after the end of the trial;

Exclusion criteria

Exclusion Criteria:

  • Subjects were excluded from the study if one or more of the following criteria were applicable

    • Participants with history of drug allergy or specific allergy;
    • Participants who had psychiatric conditions or diseases in cardiovascular, respiratory, endocrine, kidney, liver, digestive tract, skin, immune, blood, nerve and other systems;
    • Participants with history of active pathological bleeding, or bleeding tendency;
    • Participants with abnormal results of physical examination, vital sign examination, examination, laboratory test in the screening period which were judged as by clinicians;
    • Participants with significant liver fibrosis or cirrhosis;
    • Participants with symptoms or a history of hepatic decompensation;
    • Participants with a history or suspected risk of liver cancer;
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Cohort A (HT-101 + HT-102)

    Participants will receive HT-101 injection combined with HT-102 injection, administered once every 4 weeks for 24weeks

    Drug: HT-101 · Drug: HT-102

  • Experimental
    Cohort B (placebo;HT-101+HT-102)

    Participants will receive Placebo injection, administered Q4W for 8 weeks and sequential dosed with HT-101 injection combined with HT-102 injection, administered once every 4 weeks for another 16 weeks

    Drug: HT-101 · Drug: HT-102 · Drug: HT-101 placebo · Drug: HT-102 placebo

Interventions

  • DrugHT-101

    HT-101 given by subcutaneous injection

  • DrugHT-102

    HT-102 given by subcutaneous injection

  • DrugHT-101 placebo

    HT-101 placebo given by subcutaneous injection

  • DrugHT-102 placebo

    HT-102 placebo given by subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Proportion of participants achieving HBsAg < lower limit of detection (LOD) 0.05 International Unit/mL (IU/mL) and HBV DNA < lower limit of quantitation (LLOQ) with or without anti-HBs seroconversion at W60

    Time frame: From enrollment to the end of treatment at up to 60 weeks

Secondary outcomes

  1. Proportion of participants achieving HBV DNA lower than LLOQ after stopping all anti-HBV treatment

    Time frame: From enrollment to the end of treatment at up to 60 weeks

  2. HBsAg loss rate at W24, W36, W60

    Time frame: From enrollment to the end of treatment at up to 60 weeks

  3. Maximum Change of Serum HBsAg From Baseline Description

    Maximum change of serum HBsAg from Day 1 until 36 weeks post last dose (negative values mean reductions from baseline, positive values mean increased from baseline)

    Time frame: Up to 36 weeks

  4. Maximum Change of Serum HBV DNA From Baseline Description

    Maximum change of serum HBV DNA from Day 1 until 36 weeks (negative values mean reductions from baseline, positive values mean increased from baseline)

    Time frame: Up to 36 weeks.

  5. Incidence of adverse events (AEs) and serious adverse events (SAEs)

    Number of subjects with adverse events (AEs) and serious adverse events (SAEs) assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0

    Time frame: From enrollment to the end of treatment at up to 60 weeks

  6. Clinically significant abnormalities

    Number of subjects with clinically significant abnormalities in vital signs, electrocardiogram (ECG), and laboratory parameters graded by CTCAE v5.0

    Time frame: From enrollment to the end of treatment at up to 60 weeks

  7. Maximum Plasma Concentration (Cmax)

    Cmax of HT-101 and its metabolite in plasma. First administration: Predose 1 hour; Postdose 2 hours, 4 hours, 6 hours, 8 hours. Changes in the concentration of HT-102 in serum, From Day1 until 36 weeks.

    Time frame: HT-101: From predose 1 hour to postdose 8 hours. HT-102: UP to 36 weeks.

  8. Time to Reach Maximum Plasma Concentration (Tmax)

    Tmax of HT-101 and its metabolite in plasma. First administration: Predose 1 hour; Postdose 2 hours, 4 hours, 6 hours, 8 hours. Changes in the concentration of HT-102 in serum, From Day1 until 36 weeks.

    Time frame: HT-101: From predose 1 hour to postdose 8 hours. HT-102: UP to 36 weeks.

  9. Area Under the Plasma Concentration Versus Time Curve (AUC)

    AUC of HT-101 and its metabolite from time 0 to last measurable time. First administration: Predose 1 hour; Postdose 2 hours, 4 hours, 6 hours, 8 hours. Changes in the concentration of HT-102 in serum, From Day1 until 36 weeks.

    Time frame: HT-101: From predose 1 hour to postdose 8 hours. HT-102: UP to 36 weeks.

  10. Titers of Anti-drug Antibody (ADA) to HT-102 or HT-101

    ADA analysis for predose 36weeks

    Time frame: UP to 36 weeks

07

Study locations

12 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Feb 2027, 15 months after the start.

Of 75 industry-sponsored phase 2 interventional studies under Hepatitis B, Chronic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 39. This study's planned 15 months is below that.

Counting every sponsor, half of 87 studies reached it within 23 months; a quarter within 16 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Nov 24, 2025
StartActual
Nov 5, 2025
Primary completionEst.
Feb 2027
CompletionEst.
May 2027
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
2 inclusion criteria edited, 4 added; 8 exclusion criteria added, 1 removed
What changed in the criteria
Inclusion criteria
  • AddedPatient with CHB;
  • EditedPatient with CHB Male subjects weighed ≥ 45.0 kg, female subjects weighed ≥ 40.0 kg, with a body mass index (BMI) between 19.0 and 30.0 kg/m\^2 (inclusive); Chronic HBV infection for >/= 6 months; The quantitation level of HBsAg was > 100 IU/mL and <3000 IU/mL; The quantitation level of HBV DNA <LLOQ;
  • AddedChronic HBV infection for >/= 6 months;
  • AddedThe quantitation level of HBsAg was > 100 IU/mL and <3000 IU/mL; The quantitation level of HBV DNA <LLOQ;
  • AddedOn Nas therapy for >/= 6 months at the time of screening;
  • EditedOn Nas therapy for >/= 6 months at the time of screening Subjects promised to use effective contraception for at least 1 month before screening, and have no fertility, donate sperm or eggs and voluntarily take highly effective physical contraception (including partners) during the trial and within 3 months after the end of the trial;
Exclusion criteria
  • RemovedSubjects were excluded from the study if one or more of the following criteria were applicable Participants with history of drug allergy or specific allergy; Participants who had psychiatric conditions or diseases in cardiovascular, respiratory, endocrine, kidney, liver, digestive tract, skin, immune, blood, nerve and other systems; Participants with history of active pathological bleeding, or bleeding tendency; Participants with abnormal results of physical examination, vital sign examination, ECG examination, laboratory test in the screening period which were judged as clinically significant by clinicians; Participants with significant liver fibrosis or cirrhosis; Participants with symptoms or a history of hepatic decompensation; Participants with a history or suspected risk of liver cancer;
  • AddedSubjects were excluded from the study if one or more of the following criteria were applicable
  • AddedParticipants with history of drug allergy or specific allergy;
  • AddedParticipants who had psychiatric conditions or diseases in cardiovascular, respiratory, endocrine, kidney, liver, digestive tract, skin, immune, blood, nerve and other systems;
  • AddedParticipants with history of active pathological bleeding, or bleeding tendency;
  • AddedParticipants with abnormal results of physical examination, vital sign examination, ECG examination, laboratory test in the screening period which were judged as clinically significant by clinicians;
  • AddedParticipants with significant liver fibrosis or cirrhosis;
  • AddedParticipants with symptoms or a history of hepatic decompensation;
  • AddedParticipants with a history or suspected risk of liver cancer;
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Eligibility 2 inclusion criteria edited, 4 added; 8 exclusion criteria added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • AddedPatient with CHB;
    • EditedPatient with CHB Male subjects weighed ≥ 45.0 kg, female subjects weighed ≥ 40.0 kg, with a body mass index (BMI) between 19.0 and 30.0 kg/m\^2 (inclusive); Chronic HBV infection for >/= 6 months; The quantitation level of HBsAg was > 100 IU/mL and <3000 IU/mL; The quantitation level of HBV DNA <LLOQ;
    • AddedChronic HBV infection for >/= 6 months;
    • AddedThe quantitation level of HBsAg was > 100 IU/mL and <3000 IU/mL; The quantitation level of HBV DNA <LLOQ;
    • AddedOn Nas therapy for >/= 6 months at the time of screening;
    • EditedOn Nas therapy for >/= 6 months at the time of screening Subjects promised to use effective contraception for at least 1 month before screening, and have no fertility, donate sperm or eggs and voluntarily take highly effective physical contraception (including partners) during the trial and within 3 months after the end of the trial;
    Exclusion criteria
    • RemovedSubjects were excluded from the study if one or more of the following criteria were applicable Participants with history of drug allergy or specific allergy; Participants who had psychiatric conditions or diseases in cardiovascular, respiratory, endocrine, kidney, liver, digestive tract, skin, immune, blood, nerve and other systems; Participants with history of active pathological bleeding, or bleeding tendency; Participants with abnormal results of physical examination, vital sign examination, ECG examination, laboratory test in the screening period which were judged as clinically significant by clinicians; Participants with significant liver fibrosis or cirrhosis; Participants with symptoms or a history of hepatic decompensation; Participants with a history or suspected risk of liver cancer;
    • AddedSubjects were excluded from the study if one or more of the following criteria were applicable
    • AddedParticipants with history of drug allergy or specific allergy;
    • AddedParticipants who had psychiatric conditions or diseases in cardiovascular, respiratory, endocrine, kidney, liver, digestive tract, skin, immune, blood, nerve and other systems;
    • AddedParticipants with history of active pathological bleeding, or bleeding tendency;
    • AddedParticipants with abnormal results of physical examination, vital sign examination, ECG examination, laboratory test in the screening period which were judged as clinically significant by clinicians;
    • AddedParticipants with significant liver fibrosis or cirrhosis;
    • AddedParticipants with symptoms or a history of hepatic decompensation;
    • AddedParticipants with a history or suspected risk of liver cancer;

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07245953
Lead sponsor
Suzhou HepaThera Biotech Co., Ltd.
Responsible party
Sponsor
First posted
Nov 24, 2025
Start date
Nov 5, 2025
Primary completion
Feb 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Oct 29, 2026

Study contacts

Jinlin Hou
study chair · Nanfang Hospital, Southern Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HT-101

Start the discussion